Atherosclerosis in primary antiphospholipid syndrome

Paul R.J. Ames, Giovanna Scenna, Iolanda Antinolfi, Luis Lopez, Luigi Iannaccone, Eiji Matsuura, Annamaria Margarita

    Research output: Contribution to journalReview articlepeer-review

    3 Citations (Scopus)


    Antiphospholipid syndrome (APS) is the most common cause of acquired thrombophilia, but experimental and clinical evidence accumulated over the years suggest that the clinical manifestations of APS go beyond those of a simple hypercoagulable state. Although still a controversial topic, the elevated risk of atherosclerosis in systemic lupus erythematosus seems little accounted for by the presence of antiphospholipid antibodies, whereas premature atherosclerosis has been addressed in few series of patients with primary APS. The available data in primary APS suggest that traditional risk factors for atherosclerosis are less involved in arterial disease, rather antiphospholipid antibodies appear as major players. Their effect on the coagulation system, the vessel wall and on the antioxidant/oxidant balance impairs vascular homeostasis, leading to premature arterial thickening.

    Original languageEnglish
    Pages (from-to)53-60
    Number of pages8
    JournalExpert Review of Clinical Immunology
    Issue number1
    Publication statusPublished - Jan 2008


    • Antiphospholipid syndrome
    • Atherosclerosis
    • Oxidation
    • Paraoxonase
    • β-2-glycoprotein-1

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology


    Dive into the research topics of 'Atherosclerosis in primary antiphospholipid syndrome'. Together they form a unique fingerprint.

    Cite this